Fosfomycin for UTI with Non-Fermenting Gram-Negative Rods

Primary Evidence Against Use

• The European Association of Urology restricts fosfomycin to uncomplicated cystitis only, specifically excluding complicated UTIs and pyelonephritis 1
• Fosfomycin should NOT be used for complicated UTIs or pyelonephritis caused by any pathogen, including resistant organisms 2

Guideline Restrictions

• The European Association of Urology recommends fosfomycin only for uncomplicated cystitis in women caused by typical uropathogens, not for infections caused by non-fermenting organisms 1, 2

Alternative Approaches for Non-Fermenters

• Aminoglycosides show moderate-certainty evidence for complicated UTI treatment, though nephrotoxicity risk increases after 7 days 3
• Carbapenems remain standard therapy for susceptible isolates 3
• Aminoglycoside-containing combinations may improve cure rates and reduce mortality for carbapenem-resistant organisms 4
• Combination therapy is preferred over monotherapy for serious infections with non-fermenters 4

Critical Pitfalls to Avoid

• Do not use oral fosfomycin for any infection with non-fermenting organisms - it lacks sufficient data and has poor efficacy 1, 2
• Intravenous fosfomycin has only been studied in combination therapy for carbapenem-resistant Enterobacteriaceae, not non-fermenters 4

When Fosfomycin IS Appropriate

• Fosfomycin remains an excellent choice for uncomplicated cystitis in women caused by E. coli or Enterococcus, including VRE 1
• Fosfomycin is suitable for ESBL-producing Enterobacteriaceae causing uncomplicated lower UTI only 2
• A single 3-gram oral dose provides 24-48 hours of therapeutic urinary concentrations 1, 2